



PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION December 3, 2003 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 0148.1102-011	APPLICATION NO. 09/896,050	
	APPLICANT John Ghrayeb <i>et al.</i>		
	FILED DATE June 29, 2001	CONFIRMATION NO. 1490	GROUP 1644



U.S. PATENT DOCUMENTS				
EXAM- INER INITIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
MA	AB	4,381,295	26-APR-1983	Kung <i>et al.</i>

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO	
MA	AL2 ✓	EP 0 125 023 A1 ✓	14-NOV-1984	EPO	—	—
MA	AM2 ✓	EP 0 240 344 B1	07-OCT-1987	EPO	—	—
MA	AN2 ✓	EP 0 200 412 A2	10-DEC-1986	EPO	—	—
MA	AO2 ✓	EP 0 171 496 A2	19-FEB-1986	EPO	—	—
MA	AP2 ✓	EP 0 173 494 A2	05-MAR-1986	EPO	—	—
MA	AQ2 ✓	WO 86/01533 A1	13-MAR-1986	PCT	—	—
MA	AL3 ✓	EP 0 511 308 B1	04-NOV-1992	EPO	—	—

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
MA	AX5 ✓	Kong, Y. M., <i>et al.</i> , "Pathogenic Mechanisms in Murine Autoimmune Thyroiditis: Short- and Long-Term Effects of <i>in vivo</i> depletion of CD4 ⁺ and CD8 ⁺ Cells," <i>Clin. Exp. Immunol.</i> , 77:428-433 (1989).
MA	AY5 ✓	Cobbold, S.P., <i>et al.</i> , "Therapy with Monoclonal Antibodies by Elimination of T-Cell Subsets <i>in vivo</i> ," <i>Nature</i> , 312:548-551 (1984).
MA	AZ5 ✓	Mudgett-Hunter, M., <i>et al.</i> , "Binding and Structural Diversity Among High-Affinity Monoclonal Anti-Digoxin Antibodies," <i>Molecular Immunology</i> , 22(4):477-488 (1985).
MA	AR6 ✓	Playfair, J.H.L., "Antigen-Antibody Interaction and Immune Complexes," In <i>Immunology At a Glance</i> , (Blackwell Scientific Publication; London), Chapter 14 (1984).
MA	AS6 ✓	Evans, R.L., <i>et al.</i> , "Thymus-Dependent Membrane Antigens in Man: Inhibition of Cell-Mediated Lympholysis by Monoclonal Antibodies to T _{H2} Antigen," <i>Proc. Natl. Acad. Sci.</i> , 78(1):544-548 (1981).
MA	AT6 ✓	Matthews, T.J., <i>et al.</i> , "AIDS Vaccines", <i>Scientific American</i> , 259(4):98-105 (1988).

BEST AVAILABLE COPY

Handwritten signature: *RL*
 Date: 3/25/2004

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE CITATION² IN AN APPLICATION December 3, 2003 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 0148.1102-011	APPLICATION NO. 09/896,050	
	APPLICANT John Ghayeb <i>et al.</i>		
	FILING DATE June 29, 2001	CONFIRMATION NO. 1490	GROUP 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

121	AU6	van Oosten, B.W., <i>et al.</i> , "Treatment of Multiple Sclerosis with the Monoclonal Anti-CD4 Antibody cM-T412: Results of a Randomized, Double-Blind, Placebo-Controlled, MR-Monitored Phase II Trial," <i>Neurology</i> , 49:351-357 (1997).
122	AV6	Moreland, L.W., <i>et al.</i> , "Experience with a Chimeric Monoclonal Anti-CD4 Antibody in the Treatment of Refractory Rheumatoid Arthritis," <i>Clinical and Experimental Rheumatology</i> , 11(Suppl. 8):S153-S159 (1993)
123	AW6	Gill, H.S., <i>et al.</i> , "In vivo Inhibition by a Monoclonal Antibody to CD4 ⁺ T Cells of Humoral and Cellular Immunity in Sheep," <i>Immunology</i> , 77:38-42 (1992).
124	AX6	Bushell, A., <i>et al.</i> , "Transplantation Tolerance Induced by Antigen Pretreatment and Depleting Anti-CD4 Antibody Depends on CD4 ⁺ T Cell Regulation During the Induction Phase of the Response," <i>Eur. J. Immunol.</i> , 25:2643-2649 (1995).
125	AY6	Matloubian, M., <i>et al.</i> , "CD4 ⁺ Cells are Required to Sustain CD8 ⁺ Cytotoxic T-Cell Responses During Chronic Viral Infection," <i>Journal of Virology</i> , 68(12):8056-8063 (1994).
126	AZ6	Canva-Delcambre, V., <i>et al.</i> , "Treatment of Severe Crohn's Disease with Anti-CD4 Monoclonal Antibody," <i>Ailment Pharmacol. Ther.</i> , 10:721-727 (1996).
127	AR7	van Montfrans, C., <i>et al.</i> , "Immunotherapy of Crohn's Disease," <i>Mediators of Inflammation</i> , 7:149-152 (1998).
128	AS7	Reiter, C., <i>et al.</i> , "Treatment of Rheumatoid Arthritis with Monoclonal CD4 Antibody M-T151. Clinical Results and Immunopharmacologic Effects in an Open Study, Including Repeated Administration," <i>Arthritis and Rheumatism</i> , 34(5):525-536 (1991).
129	AT7	Moreland, L.W., <i>et al.</i> , "Use of a Chimeric Monoclonal Anti-CD4 Antibody in Patients with Refractory Rheumatoid Arthritis," <i>Arthritis and Rheumatism</i> , 36(3):307-318 (1993).
130	AU7	Boehringer Mannheim Biochemicals Catalogue, page 328, 1987/1988.
131	AV7	Boehringer Mannheim Biochemicals Catalogue, page 109, 1989.
132	AW7	Genbank Accession No. PH1224, "Ig Kappa Chain Precursor V Region (M-T151) - Mouse (fragment)," (1999) [online], [retrieved on 4/10/00]. Retrieved from www.ncbi.nlm.nih.gov:80.

BEST AVAILABLE COPY

3/25/2004

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION December 3, 2003 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 0148.1102-011	APPLICATION NO. 09/896,050	
	APPLICANT John Ghrayeb <i>et al.</i>		
	FILING DATE June 29, 2001	CONFIRMATION NO. 1490	GROUP 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AX7	Genbank Accession No. PH1225, "Ig Heavy Chain Precursor V Region (M-T151) - Mouse (fragment)," (1999) [online], [retrieved on 4/10/2000]. Retrieved from www.ncbi.nlm.nih.gov:80.
AY7	Genbank Accession No. S19970, "Ig Kappa Chain V Region (M-T151) - Mouse (fragment)," (1999) [online], [retrieved on 4/10/2000]. Retrieved from www.ncbi.nlm.nih.gov:80.
AZ7	Genbank Accession No. S19963, "Ig Heavy Chain V Region (M-T151) - Mouse (fragment)," (1996) [online], [retrieved on 4/10/2000]. Retrieved from www.ncbi.nlm.nih.gov:80.
AR8	Genbank Accession No. CAA46223, "Alpha CD4 mAb Immunoglobulin Light Chain VJ Region [Mus musculus]," (1997) [online], [retrieved on 4/10/00]. Retrieved from www.ncbi.nlm.nih.gov:80.
AS8	Genbank Accession No. CAA46215, "Alpha CD4 mAb Immunoglobulin Heavy Chain VDJ Region [Mus Musculus]," (1997) [online], [retrieved on 4/10/00]. Retrieved from www.ncbi.nlm.nih.gov:80.
AT8	Genbank Accession No. AAB24319, "Anti-CD4 mAb M-T151 Variable Region Heavy Chain [J4, Chimeric Antibody] [Mice, Hybridoma Cells, Peptide Partial, 139 aa]," (1993) [online], [retrieved on 4/10/00]. Retrieved from www.ncbi.nlm.nih.gov:80.
AU8	Genbank Accession No. AAB24318, "Anti-CD4 mAb M-T151 Variable Region Light Chain [J2, Chimeric Antibody] [Mice, Hybridoma Cells, Peptide Partial, 127 aa]," (1993) [online], [retrieved on 4/10/00]. Retrieved from www.ncbi.nlm.nih.gov:80.
AV8	Genbank Accession No. X65095, "M. musculus mRNA for IG Light Chain VJ Region (M-T151)," (1997) [online], [retrieved on 4/10/2000]. Retrieved from www.ncbi.nlm.nih.gov:80.
AW8	Genbank Accession No. X65087, "M. musculus mRNA for IG Heavy Chain VDJ Region (M-T151)," (1997) [online], [retrieved on 4/10/00]. Retrieved from www.ncbi.nlm.nih.gov:80.
AX8	Genbank Accession No. S50263, "Ig VH=anti-CD4 mAb M-T151 Variable Region Heavy Chain [J4, Chimeric Antibody] [Mice, Hybridoma Cells, mRNA Partial, 417 nt]," (1993) [online], [retrieved on 4/10/00]. Retrieved from www.ncbi.nlm.nih.gov:80.
AY8	Genbank Accession No. S50261, "Ig VL=anti-CD4 mAb M-T151 Variable Region Light Chain [J2, Chimeric Antibody] [Mice, Hybridoma Cells, mRNA Partial, 381 nt]," (1993) [online], [retrieved on 4/10/00]. Retrieved from www.ncbi.nlm.nih.gov:80.
AZ8	Declaration of Dr. Christian Reiter executed on November 2, 1994, filed in opposition proceeding in EP 0 511 308 (Reference AL3).

BEST AVAILABLE COPY

3/25/2008

PTO-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION December 3, 2003 <small>(Use several sheets if necessary)</small>	ATTORNEY DOCKET NO. 0148.1102-011	APPLICATION NO. 09/896,050	
	APPLICANT John Ghrayeb <i>et al.</i>		
	FILING DATE June 29, 2001	CONFIRMATION NO. 1490	GROUP 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AR9	Declaration of Dr. Margaret R. Dalesandro executed on July 1, 1998, filed in opposition proceeding in EP 0 511 308 (Reference AL3).

RECEIVED
DEC 11 2003
TECH CENTER 1600/2900

3/25/2007

BEST AVAILABLE COPY